Dehydration News and Research

Latest Dehydration News and Research

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

Energy drink consumption can improve performance in young sports people: Study

Consuming energy drinks during team sports could help young people perform better, a study suggests. Sports scientists found that 12-14 year olds can play for longer in team games when they drink an isotonic sports drink before and during games.

9 Sep 2010

Studies show diagnostic errors cause adverse events than medication errors

Studies show that diagnostic errors cause twice as many adverse events as medication errors, but the subject has received little attention; Pennsylvania Patient Safety Authority reviews 100 events related to diagnostic error.

3 Sep 2010

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.

3 Sep 2010

Death toll expected to rise as flooding subsides in some parts of Pakistan

Pakistani government officials say the death toll from the country's flooding stands at more than 1,600 and it could rise significantly as flood waters recede and more bodies are identified, CNN reports (8/28). "There is no official estimate of the number of missing because mass displacements have made accounting for them almost impossible," according to Reuters (Haider, 8/29).

31 Aug 2010

Marathon running does not cause sustained heart damage

A study of 167 amateur runners at the 2006 and 2007 Berlin marathons is lowering concerns that this type of activity leads to sustained heart damage, particularly among older competitors. Marathons are becoming an increasingly popular challenge for amateur runners wanting to test their endurance over the classic 26-mile distance. The medical community, however, has long been concerned about how marathons impact the heart - and it has not yet been shown if the effects vary among different age groups or genders.

31 Aug 2010

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010.

25 Aug 2010

EPA selects Precision Antibody to develop monoclonal antibodies for 'Crypto' intestinal parasite

Precision Antibody™ announced today its selection by the United States Environmental Protection Agency (EPA) to develop monoclonal antibodies to two species of Cryptosporidium, an intestinal parasite that has emerged over the past 20 years as one of the most common causes of waterborne illness in the United States.

24 Aug 2010

Cholera outbreaks on the rise, WHO expert says

A recent increase in the number of cholera outbreaks is threatening populations in pockets of the world, Claire-Lise Chaignat, WHO's cholera group coordinator, said on Thursday, Agence France-Presse reports. "Cholera is transmitted by water but also by food that had been contaminated by unclean water," the news service writes. "It causes serious diarrhoea and vomiting, leading to dehydration. With a short incubation period, it can be fatal if not treated in time," AFP writes.

21 Aug 2010

Sport Endurance develops new formula that enables safe consumption of Creatine

Sport Endurance, Inc, a health supplement company, has developed a revolutionary formula that enables the safe consumption of Creatine, a proven muscle-building and performance enhancing dietary supplement.

17 Aug 2010

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen today announced top-line results from a randomized Phase 3 trial evaluating Vectibix as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to chemotherapy alone.

12 Aug 2010

First Salmonella lawsuit filed against Yum Brands

The first Salmonella lawsuit has been filed in the pair of Salmonella outbreaks that has sickened 155 people in 21 states. The lawsuit was filed against Yum! Brands (the parent company of Taco Bell) in the Commonwealth of Kentucky, Franklin County Circuit Court. The lawsuit was filed on behalf of a Scott county resident by food safety law firm Marler Clark.

7 Aug 2010

Project for improving nurses' assessment skills to detect and alleviate delirium symptoms

In the future, nurses may more accurately detect and alleviate symptoms of delirium in persons with dementia, thanks to a five-year, $2.7-million grant from the National Institute of Nursing Research.The project, led by Donna Fick, professor of nursing, Penn State, seeks to improve nurses' assessment skills and reduce the use of drugs to treat delirium and dementia.

5 Aug 2010

Consumers who have MMS should stop using it immediately, FDA warns

The U.S. Food and Drug Administration is warning consumers not to take Miracle Mineral Solution, an oral liquid solution also known as "Miracle Mineral Supplement" or "MMS." The product, when used as directed, produces an industrial bleach that can cause serious harm to health.

31 Jul 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

Researchers unveil mechanism of cholera bacteria to create cell energy

Researchers have found that an enzyme in the bacteria that causes cholera uses a previously unknown mechanism in providing the bacteria with energy. Because the enzyme is not found in most other organisms, including humans, the finding offers insights into how drugs might be created to kill the bacteria without harming humans.

29 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

NPS completes patient randomization in GATTEX Phase 3 study for PN dependent short bowel syndrome

NPS Pharmaceuticals, a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of patient randomization in its Phase 3 registration study of GATTEX® (teduglutide). The double-blind, placebo-controlled safety and efficacy study, which is known as STEPS, is being conducted in patients with parenteral nutrition (PN) dependent short bowel syndrome (SBS) and is now fully randomized with 86 patients.

23 Jul 2010

Iced tea increases risk of kidney stone formation and surgery

Unfortunately, for health reasons, Mulac has been forced to go cold turkey. All the iced tea he was downing helped to bring on an excruciating bout of kidney stones that eventually led to surgery at Loyola University Hospital in Maywood, Ill.

21 Jul 2010